Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing agreement with Germany’s BioNTech SE (NASDAQ: BNTX). Under the terms of this deal, Doer Bio will provide BioNTech with a global license to research, develop, manufacture, and commercialize innovative biological drugs targeting an undisclosed therapeutic target, leveraging an innovative discovery made by Doer Bio. In return, Doer Bio will receive advance payments and is eligible for potential development, regulatory, and commercial milestone payments.
Doer Bio’s Proprietary Technologies and Focus on Metabolic Diseases and Cancers
Doer Bio specializes in the discovery and development of multi-specific biological drugs aimed at treating metabolic diseases and cancers. The company boasts several proprietary platform technologies, including xLONGylation, MultiBody, AccuBody, and SMART-VHBody, which position it at the forefront of innovative drug development. These technologies enable the creation of cutting-edge therapies that have the potential to transform the treatment landscape for various diseases.
Collaboration with BioNTech to Accelerate Drug Discovery and Commercialization
The partnership with BioNTech SE is a strategic move that will accelerate the global development and commercialization of the targeted biological drugs. By combining Doer Bio’s innovative discovery with BioNTech’s extensive experience in the field, the collaboration aims to bring new and effective treatments to patients worldwide.-Fineline Info & Tech
